CytomX Therapeutics
CTMX
49 hedge funds and large institutions have $226M invested in CytomX Therapeutics in 2016 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 19 increasing their positions, 11 reducing their positions, and 6 closing their positions.
73% more repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 11
17% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 6
2% more funds holding
Funds holding: 48 → 49 (+1)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
37% less capital invested
Capital invested by funds: $360M → $226M (-$134M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
+$1.39M |
| 2 |
GC
Globeflex Capital
San Diego,
California
|
+$819K |
| 3 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
+$694K |
| 4 |
VIA
Vident Investment Advisory
Alpharetta,
Georgia
|
+$491K |
| 5 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
+$444K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$485K |
| 2 |
D.E. Shaw & Co
New York
|
-$444K |
| 3 |
VMI
VHCP Management II
New York
|
-$350K |
| 4 |
Goldman Sachs
New York
|
-$319K |
| 5 |
QSS
Quantitative Systematic Strategies
Ponte Vedra Beach,
Florida
|
-$300K |
CTMX Hedge Fund Activity: Q1 2016 in Review
49 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in CytomX Therapeutics (CTMX) for Q1 2016, worth a combined $226M — down 37% from $360M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new CTMX positions and 6 closed out — a net gain of 1 holder — while 19 added to existing stakes and 11 trimmed.
The largest buyer was Perceptive Advisors, adding an estimated $1.39M. The largest seller was Susquehanna International Group, exiting entirely with an estimated $485K sold.
- 49 institutional investors held CytomX Therapeutics (CTMX) as of Q1 2016, up from 48 in Q4 2015.
- Funds reported $226M of CytomX Therapeutics stock for Q1 2016, down 37% quarter-over-quarter.
- 7 funds opened new CytomX Therapeutics positions in Q1 2016 and 6 closed out, a net change of +1 holder.
- The largest CytomX Therapeutics buyer in Q1 2016 was Perceptive Advisors, an estimated $1.39M added.
- The largest CytomX Therapeutics seller in Q1 2016 was Susquehanna International Group, an estimated $485K sold.
Based on aggregated 13F filings for Q1 2016.